Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

7 Cheap Stocks to Buy If You Only Have $100 to Spend

By Chris Markoch, InvestorPlace Contributor

You can find many good stocks to buy for under $10. And here are seven cheap stocks that are good buys even if you only have $100 to spend.

QuantumScape Is Stuck in Neutral, but It May Still Pay Off for Patient Investors

By Chris Markoch, InvestorPlace Contributor

QS stock may have found a floor since the onset of the Russian invasion of Ukraine. That may not be perfect for investors, but it’s a start.

Block Is Telling a Growth Story That Investors Simply Aren’t Buying

By Chris Markoch, InvestorPlace Contributor

Despite a strong earnings report, SQ stock can’t stop its slide. Investors are not buying what Block is selling. And neither should you.

Asana Tells a Growth Story, But it’s Not One Investors Want to Hear

By Chris Markoch, InvestorPlace Contributor

Despite steady top-line growth, ASAN stock is down 62% from its 52-week high as investors continue their flight to value.

Is it Finally SAFE to Invest in Tilray Stock?

By Chris Markoch, InvestorPlace Contributor

The SAFE Banking Act may be the catalyst that long-suffering investors in TLRY stock have been waiting for, but it pales in comparison to legalization.

Load More